Skip to main content

Table 1 Baseline cohort (n = 4001)

From: Is pathology necessary to predict mortality among men with prostate-cancer?

Age (years)at index date, median (IQR)   75 (72-79)
Follow-up time (years), mean (SD) before prostate cancer   2.9 (1.2-5.2)
Follow-up time (years), mean (SD) from prostate cancer to end of follow up   4.7 ( 2.7-7.3)
Gleason grade at presentation Low grade 1574 (39.3%)
Intermediate 1420 (35.4%)
High grade 1007 (25.2%)
Primary treatment Surgery 317 (7.9%)
Radiation 937 (33.2%)
Watchful waiting 1740 (43.5%)
ADT 1329 (46%)
Volume of prostate cancer High (>30%) 2245 (56%)
Low (≤30%) 1753 (44%)
TUR diagnosis n (%)   681 (18%)
Co morbidity sum of ADGs n (%) 5 or less 1212 (30.3%)
6-9 1951 (49%)
10 or more 838 (20.7%)
*SES status n (%) 1 769 (20.3%)
2 838 (22.2%)
3 764 (20.2%)
4 693 (18.3%)
5 717 (19%)
Urban n (%)   545 (85.6%)
Prostate cancer specific death n (%)   321 (8.5%)
Overall mortality n (%)   1395 (35%)